Achaogen Inc (AKAO.OQ)
16 Nov 2018
Tue, Jun 26 2018
June 26 Achaogen Inc said on Tuesday U.S. health regulators cleared its antibiotic to treat adults with complicated urinary tract infections, but declined approval for treating bloodstream infections.
June 26 The U.S. Food and Drug Administration approved Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, the company said on Tuesday.
- Synergy Collapse Due To Toxic CRG Loan Sends Shockwaves Throughout Biotech Sector
- Achaogen (AKAO) CEO Blake Wise on Q3 2018 Results - Earnings Call Transcript
- Does Achaogen Have The Operational Runway Required To Deliver Value?
- Achaogen's Zemdri: Blockbuster Potential For A Pittance
- Contrafect: A New Anti-Microbial Treatment Paradigm
- Forensic Stock Selections For October - Positive Forensic Returns Averaging +52.83%